New Blood Test Method Predicts Biological Age via IgG Glycans
Researchers at Fudan University developed a method for precise measurement of glycans on IgG antibodies, creating a highly accurate model for predicting biological age. This opens up opportunities for monitoring and potentially slowing down aging processes.
Glycan Trap: Why Fudan University's New 'Aging Clock' Is a Threat to Epigeneticists and an Opportunity for Big Pharma
The Core: What's Really Happening
On May 13, 2026, researchers from Fudan University published a paper in Engineering that most media framed as 'yet another aging clock.' Formally, that's true: the team led by Huijuan Zhao developed a method for absolute quantification of N-glycans on IgG and built the abGlycoAge model for predicting biological age.
But if you're inside the industry—and I am, consulting two diagnostic startups and one venture capital fund—you see a completely different picture. The real sensation isn't the 'clock,' but the IgG-Ny experiment. Eighty-week-old mice were injected with IgG carrying a 'young' glycosylation pattern, and they showed reduced interleukin-6, TNF-α, and β-galactosidase staining in the brain, kidneys, and lungs. This isn't just a correlation of glycans with age. It's proof that modifying sugar residues on antibodies can reverse some aspects of aging.
The longevity diagnostics market, where Horvath, Hannum, GlycanAge, and others already operate, has received not a new chronometer, but a claim for a therapeutic platform. The difference is fundamental.
Timeline and Context
To understand the significance of Zhao's work, you need to see the timeline of glycan research:
- January 2022 — Aging publishes a catalog of 15 omic clocks, showing that IgG glycomic clocks correlate with chronological age at r=0.74–0.75, second only to epigenetic clocks. It was also noted that epigenetic and IgG glycomic clocks 'track generalized aging,' while other omics track specific risks.
- 2024 — GlycanAge (company of Gordan Lauc, a pioneer in glycomics) raises $4.2 million in seed funding from LAUNCHub Ventures and Kadmos Capital.
- December 2025 — GlycanAge raises an additional EUR 7.4 million ($8.7 million), lead investor Fifth Quarter Ventures. The company announces plans to scale to 10,000+ tests per month and enter the US market.
- January 2026 — GlycanAge announces clinical validations in cardiology and women's health (MenoAge for perimenopause).
- May 13, 2026 — Publication of Zhao's group with a key difference: absolute quantification instead of relative.
The context here is intense: GlycanAge built its business on relative measurements of 29 glycans. The Fudan team shifted the game to absolute concentrations of GP3 and GP8. It's like moving from 'you look older than your years' to 'your biological age is 47.3 years with a confidence interval of ±2.1.' Investors love that; competitors don't.
Who Wins and Who Loses
Winners:
- Novartis and Roche — companies with active programs in IgG biosimilars. The IgG-Ny technology demonstrated by Zhao's group essentially opens a new therapeutic direction: 'glycoengineering of aging.' If modified antibodies reduce aging markers in the brain, kidneys, and lungs, this is a potential market worth tens of billions of dollars. I wouldn't be surprised if Roche has already requested a patent license.
- GlycanAge — paradoxically, the competitors' publication plays into their hands. Every new article linking glycans to aging legitimizes their business model. With EUR 7.4 million in fresh investments and plans to deploy in 5–8 hospitals, they are in an ideal position: the market is heated, technological noise is growing, and their own clinical data is accumulating.
- Chinese CROs — the study was conducted on C57BL/6 mice using MALDI-TOF-MS. This is standard, relatively inexpensive equipment. Scaling the protocol to human cohorts can be done quickly, and Chinese contract laboratories can already offer an 'abGlycoAge package' for $150–250.
Losers:
- Epigenetic clock makers. Horvath, Hannum, PhenoAge—all require expensive sequencing or microarrays. The cost per test is $300–500. A glycan test for GP3 and GP8 could potentially be three times cheaper. And when accuracy is comparable, price wins.
- Consumer biohacking panels. Companies like InsideTracker, which mix clinical markers with epigenetics, will face a simple question: 'Do you measure glycans in absolute concentrations?' If the answer is 'no,' the premium client walks away.
What the Media Isn't Saying
Non-obvious insight: IgG-Ny is not proof of concept for an 'anti-aging drug.' It's proof of concept for immune reprogramming through glycoengineering.
Most commentators saw Zhao's work as a diagnostic tool. But reread the part of the paper where mice were injected with IgG carrying 'young' glycans. The reduction in IL-6, TNF-α, and β-galactosidase is a pharmacodynamic response. Essentially, the researchers showed that you can take IgG, change its glycosylation pattern, and obtain a molecule that actively suppresses inflammation and cellular senescence.
Why this is more important than any clock: clocks tell you you're aging. IgG-Ny says, 'Here's a lever to slow it down.' Investors pay for levers, not chronometers.
Second underestimated point: Zhao's group identified specific genes—Derl3, Smarcb1, Ankrd55, Tbkbp1, Slc38a10—whose expression changes during B-cell aging and is partially restored by caloric restriction. This means that the production of 'old' glycans is not passive wear and tear, but an active, regulated process. Theoretically, targeting these genes could make B-cells produce 'young' glycans without external IgG-Ny administration. That's the next frontier, and patents for it haven't been claimed yet.
Forecast: Next 30 Days and 90 Days
30 days (by June 22, 2026):
- GlycanAge will announce interim results of its cardiology validations, emphasizing 'absolute quantification' as a response to the competitors' publication. I expect a press release with wording like 'our platform also supports absolute measurements.'
- One of the large pharma companies (my candidate is Johnson & Johnson, given their monoclonal antibody portfolio) will initiate due diligence on IgG glycoengineering. The information won't be public, but it will surface in investor newsletters.
- Chinese biobanks will start requesting the inclusion of glycan panels in long-term cohort study protocols.
90 days (by August 20, 2026):
- GlycanAge will close a bridge Series B round of at least $15 million, using the hype around Zhao's publication as a bargaining lever. The company's valuation will exceed $100 million.
- The first preprint on applying abGlycoAge to a human cohort will appear (most likely from Fudan University itself or its partners). If the correlation with chronological age exceeds r=0.85, the market will begin to reassess the entire glycan diagnostics niche.
- I expect one of the major diagnostic holdings—LabCorp or Quest Diagnostics—to announce a partnership with a glycan platform to bring a biological age test to the US market. Deal size: $20–50 million upfront plus royalties.
Bottom line: The publication by Zhao and colleagues on May 13, 2026, is not about diagnostics. It's an announcement of the birth of a new therapeutic modality. IgG glycoengineering allows not just measuring aging but intervening in it. Those betting on longevity should shift focus from epigenetic clocks to the B-cell glycan axis. It's currently empty, patents aren't snatched up, and the proof-of-concept is already published. Play ahead of the curve.
— Editorial Team
